NL-OMON43019
Withdrawn
Phase 4
A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPin study) - STEPin
TFS Trial Form Support BV0 sites20 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- plaque psoriasis
- Sponsor
- TFS Trial Form Support BV
- Enrollment
- 20
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Aged 18 to 40 years inclusive
- •\* moderate to severe plaque psoriasis with either new onset or lasting for at least 5 years.
- •Additional inclusion criteria may apply , please refer to the protocol.
Exclusion Criteria
- •\* Forms of psoriasis other than plaque\-type (e.g., pustular, erythrodermic, guttate, light sensitive, drug induced) ;\* Ongoing use of prohibited treatments;\* Pregnant or nursing (lactating) women ;\* Women of child\-bearing potential not willing to use contraception;\*Active ongoing inflammatory diseases other than psoriasis or psoriatic arthritis that might confound the evaluation of the benefit of secukinumab therapy ;Additional exclusion criteria may apply , please refer to the protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisEUCTR2015-002423-26-SEovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-EEovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002423-26-FIovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000018190Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002423-26-HUovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002423-26-BGovartis Pharma Services AG196